Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G‐CSF in multiple myeloma: A pilot study. Issue 10 (29th July 2017)

• Record Type: Journal Article
• Authors: Shastri, Aditi; Budhathoki, Anjali; Barta, Stefan K.; Kornblum, Noah; Derman, Olga; Battini, Ramakrishna; Raghupathy, Radha; Verma, Amit K.; Frenette, Paul S.; Braunschweig, Ira; Janakiram, Murali
• Is Part Of: American journal of hematology. Volume 92:Issue 10(2017:Oct.)
• Page Start: 1047
• Page End: 1051
• Publication Date: 2017-07-29
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24843
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Hematopoietic stem cell (HSC) release is positively regulated by the sympathetic nervous system through the β3 adrenergic receptor. Preclinical studies have demonstrated that the combination of desipramine and G‐CSF resulted in improved HSC mobilization. Here, we present the results of an open‐label single‐arm pilot study in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) to assess the safety and efficacy of desipramine combined with G‐SCF to induce HSC mobilization. The primary endpoint was safety of the combination including engraftment kinetics. The secondary endpoint was the proportion of patients who collected ≥5 × 10 6 CD34 + cells/kg. Outcomes were compared with historical matched controls during the same time period with multiple myeloma mobilized with G‐CSF. All study patients received desipramine 100 mg daily for 7 days, starting 4 days prior to G‐CSF administration (D‐3) and continued taking it along with G‐CSF for a total of 7 days. Six of ten patients enrolled completed the protocol with minimal side effects. All of them achieved the target collection of 5 × 10 6 CD34 cells/kg in a median of 1.5 apheresis session with two patients needing additional plerixafor (16%), while 11 out of 13 patients (85%) achieved the target of 5 × 10 6 CD34 cells/kg in the historical control group in a median of 2 apheresis procedures and seven patients needed plerixafor (54%). The combination of desipramine and G‐CSF is safe and signals improved mobilization over G‐CSF alone, providing a possible alternative means of mobilization that needs further investigation.